Repeated Exposures to Subthreshold Doses of Chlorpyrifos in Rats: Hippocampal Damage, Impaired Axonal Transport, and Deficits in Spatial Learning

A. V. TERRY, JR., J. D. STONE, J. J. BUCCAFUSCO, D. W. SICKLES, A. SOOD, and M. A. PRENDERGAST

Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy (Augusta Campus) (A.V.T.), Alzheimer’s Research Center and Department of Pharmacology and Toxicology (A.V.T., J.J.B., A.S.), and Department of Cell Biology and Anatomy (J.D.S., D.W.S.), Medical College of Georgia, Augusta, Georgia; Department of Veterans Affairs Medical Center (A.V.T., J.J.B.), Augusta, Georgia; and Department of Psychology (M.A.P.), University of Kentucky, Lexington, Kentucky

Received July 18, 2002; accepted December 11, 2002

ABSTRACT

Organophosphorus (OP) compounds are detectable in the environment for years after use and endanger many populations. Although the effects of acutely toxic doses of many OP compounds are well described, much less is known about repeated low-level exposures. The purpose of these studies was to further evaluate potential toxicological effects of the extensively used OP pesticide chlorpyrifos (CPF) in rats. CPF, across a range of subthreshold doses (i.e., for acute toxicity), reduced rearing and sniffing activity and the magnitude of weight gain over 14 days of repeated exposure. Performance in a spatial learning task was impaired after 14 days of exposure to CPF (18.0 and 25.0 mg/kg) when testing was initiated 24 h after the last injection but not after a 14-day washout. However, inhibition of both fast anterograde and retrograde axonal transport was observed for up to 20 days after exposure to 25.0 mg/kg CPF. Studies using hippocampal cultures indicated that 8 days of continuous exposure to the parent compound, CPF (100 μM), resulted in cell toxicity and death. Furthermore, a dose (2.5 mg/kg) of CPF that had no effects on weight gain or memory performance when administered 5 days per week over 38 days impaired forelimb grip strength in the later days of testing. Collectively, these results indicate that repeated exposures to subthreshold doses of CPF may lead to growth retardation, behavioral abnormalities, and muscle weakness. Some of these symptoms may be attributed to effects of the OP on axonal transport.

A dramatic increase in the agricultural, industrial, and household use of pesticides over the past several decades (U.S. Environmental Protection Agency, 1999) has paralleled impressive improvements in farming productivity (U.S. General Accounting Office, U.S. Agriculture, 1995), the control of debilitating vector-borne diseases (e.g., malaria, yellow fever, viral encephalitis, typhus, etc.), and “nuisance” pests (e.g., flies, roaches, ants, mosquitoes, etc.) in households, schools, and office buildings (Amdur et al., 1991). A consequence of such widespread use, however, is that pesticide residues are now among the most ubiquitous synthetic chemicals in our environment, detectable in the tissues of humans worldwide (Weiss, 1997). Accordingly, inherent dangers to the public health and environment persist, since no pesticide is completely innocuous, and all carry significant toxicological risks. In fact, the most recent statistical estimates indicate that a minimum of three million pesticide poisonings occur annually, resulting in up to 220,000 deaths worldwide (Jeyaratnam, 1990).

Of the wide variety of pesticide agents available, organophosphate (OP) and carbamate insecticides are the chemicals most commonly used in the United States (Aspelin, 1994). However, because of the relative frequency of use and level of toxicity of the former, approximately 80% of hospital admissions associated with pesticides are the result of OP exposure (Litovitz, 1991). Nevertheless, many exposures, especially if they do not require hospitalization, undoubtedly go unreported (Weiss, 1997), and as a consequence, little is known about the long-term adverse effects of chronic or repeated (subthreshold) exposures to OPs.

The broad-spectrum OP, chlorpyrifos (O,O-diethyl O-3,5,6-trichloro-2-pyridinyl phosphorothioate; CPF), is one of the most extensively used agricultural pesticides in the world. A study published in 1995 (based on measurements in 1000 individuals) indicated that up to 82% of U.S. adults had...
detectable levels of the CPF metabolite (3,5,6-trichloro-pyridinol) present in their urine (Hill et al., 1995). It should be noted that due to its widespread use and concerns regarding evidence of developmental and neurobehavioral anomalies in young animals exposed to CPF, recent restrictions on the use of the agent in households (and certain other environments) have been implemented in the United States (U.S. Environmental Protection Agency Administrator Announcement, 2000).

The extensive use of CPF over the years has been attributed to evidence that it exhibits only moderate acute toxicity in many mammalian species and a greater inhibitory potency for AChE than for neurotoxic esterase. Clinical and experimental data indicate that OP-induced delayed neuropathies (OPIDN) resulting from acute exposures to CPF require doses well in excess of the LD$_{50}$, and studies in hens show that subchronic exposures at the maximum tolerated daily dose do not result in OPIDN (Richardson, 1995). However, recovery from CPF toxicity when it does occur is unusually slow even when compared with other phosphorothioates. Furthermore, CPF has been shown to produce learning deficits in rats after acute and repeated administration (Bushnell et al., 1994; Cohn and Macphail, 1997) and to produce delayed sensory neuropathies in humans (Kaplan et al., 2000). Moreover, although CPF is well known for inhibiting AChE activity, the degree of inhibition does not correlate well with the onset of toxicity or the amount of exposure (Agency for Toxic Substances and Disease Registry, 1997). These findings support new inquiries into additional mechanisms of CPF toxicity in mammalian systems.

Several lines of evidence suggest that one mechanism underlying the delayed neurotoxicity associated with some OPs is the inhibition of axonal transport (AXT). OPs that produce delayed neurotoxicity (at high doses) cause accumulations of tubulovesicular profiles within axons prior to degeneration (Abou-Donia and Lapadula, 1990), a pathology that is consistent with the stagnation of membrane traffic (Chretien et al., 1981; Souyri et al., 1981). In one study, fast anterograde AXT was reduced by phenylphosphonothioate esters and trialkyl phosphates (Reichart and Abou-Donia, 1980). A progressive deficit of retrograde AXT was associated with the neurotoxicity of di-n-butyl dichlorvos in another study (Morett et al., 1987). It is important to note, however, that none of these studies evaluated the so-called “moderately toxic” or “non-neurotoxic” OPs (such as CPF) in a repeated low-level exposure paradigm.

The purpose of this study was, therefore, to evaluate the behavioral and neurochemical effects of repeated, subthreshold doses of CPF in rats. We assessed the effects of CPF on spatial learning in a water maze task and on both fast anterograde and retrograde axonal transport ascertained ex vivo by video-enhanced differential interference contrast microscopy. Additional in vitro experiments were designed to assess the effects of extended CPF exposure on the viability of cells in the hippocampus, a structure known to contribute significantly to spatial learning.

### Materials and Methods

#### In Vivo Studies

**Test Subjects.** Male albino Wistar rats (Harlan, Indianapolis, IN) approximately 3 months old (weighing 250–350 g) were housed individually in stainless steel mesh cages in a temperature-controlled room (22°C) with free access to food (NIH-07 formula; Harlan Teklad, Madison, WI) and water and maintained on a 12-h light/dark cycle. All procedures used during this study were reviewed and approved by the Medical College of Georgia Institutional Animal Care and Use Committee and are consistent with Association for Accreditation and Assessment of Laboratory Animal Care guidelines.

**Drug Regimens.** Each experimental group received daily subcutaneous injections of peanut oil (vehicle) or CPF dissolved in peanut oil in a volume of 1.0 ml/kg body weight for the period specified below. Please refer to Table 1 for a summary of the experimental manipulations in all test groups.

**Plasma Cholinesterase Activity.** Rats (see Table 1) were injected subcutaneously with CPF in doses ranging from 2.5 to 100 mg/kg dissolved in peanut oil. The animals were killed 24 h later by decapitation, and trunk blood was immediately collected into heparinized tubes. Plasma was separated from erythrocytes by centrifugation (4000 rpm for 15 min at 4°C) and immediately assayed spectrophotometrically using a modification of a method described in detail previously (Prendergast et al., 1998). Briefly, 100-µl plasma samples were added to 24-well plates containing the reaction mixture (7.5 nM acetylthiocholine iodide substrate and 6.9 mM dithiobisnitrobenzoic acid in phosphate buffer at pH 7.9). Absorbance at 412 nm was recorded at 25°C for 4 min with a µQuant Universal Microplate spectrophotometer (Bio-Tek Instruments, Winooski, VT). Protein concentrations were also measured spectrophotometrically using the Bio-Rad protein assay system (Hercules, CA) with bovine serum albumin as standard. Data were expressed as micromoles of

### Table 1

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose</th>
<th>$n$</th>
<th>Exposure Period</th>
<th>Measurements/Testing Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.0</td>
<td>12</td>
<td>24 h</td>
<td>→ Plasma cholinesterase</td>
</tr>
<tr>
<td>2</td>
<td>2.5</td>
<td>3</td>
<td>24 h</td>
<td>→ Plasma cholinesterase</td>
</tr>
<tr>
<td>3</td>
<td>10.0</td>
<td>4</td>
<td>24 h</td>
<td>→ Plasma cholinesterase</td>
</tr>
<tr>
<td>4</td>
<td>50.0</td>
<td>6</td>
<td>24 h</td>
<td>→ Plasma cholinesterase</td>
</tr>
<tr>
<td>5</td>
<td>100.0</td>
<td>6</td>
<td>24 h</td>
<td>→ Plasma cholinesterase</td>
</tr>
<tr>
<td>6</td>
<td>0.0</td>
<td>16</td>
<td>14 days</td>
<td>→ Weight, rearing and sniffing</td>
</tr>
<tr>
<td>7</td>
<td>2.5</td>
<td>10</td>
<td>14 days</td>
<td>→ Weight, rearing and sniffing</td>
</tr>
<tr>
<td>8</td>
<td>10.0</td>
<td>10</td>
<td>14 days</td>
<td>→ Weight, rearing and sniffing</td>
</tr>
<tr>
<td>9</td>
<td>18.0</td>
<td>10</td>
<td>14 days</td>
<td>→ Weight, rearing and sniffing</td>
</tr>
<tr>
<td>10</td>
<td>25.0</td>
<td>8</td>
<td>14 days</td>
<td>→ Weight, rearing and sniffing</td>
</tr>
<tr>
<td>11</td>
<td>0.0</td>
<td>10</td>
<td>14 days</td>
<td>→ Weight, rearing and sniffing</td>
</tr>
<tr>
<td>12</td>
<td>25.0</td>
<td>10</td>
<td>14 days</td>
<td>→ Weight, rearing and sniffing</td>
</tr>
<tr>
<td>13</td>
<td>0.0</td>
<td>6</td>
<td>38 days</td>
<td>→ Weight, grip strength</td>
</tr>
<tr>
<td>14</td>
<td>2.5</td>
<td>10</td>
<td>38 days</td>
<td>→ Weight, grip strength</td>
</tr>
</tbody>
</table>
The pool was filled with water (maintained at 25.0°C) every 1 to 2 days and monitored for signs of OP toxicity in the morning before the daily drug injection (i.e., approximately 24 h after the injection of the previous day). After a 5-min acclimation period, rearing and sniffing movements were recorded for 20 min. In addition, the animals were weighed, and the occurrence and/or frequency of other indicators of OP toxicity were recorded, including tremor, salivation, diarrhea, lacrimation, and urination. At the end of the 20-min observation period, animals were injected with CPF or vehicle and returned to their home cages.

**Water Maze Experiments. Testing Apparatus.** Maze testing was performed beginning at either 1 day (24 h) or 14 days after 2 weeks for each trial, and the latency to find the platform was recorded as a measure of visual acuity.

**Grip Strength Measurements.** Both forelimb and hindlimb grip strength (measured in kilograms of resistance) was assessed for each subject in groups 13 and 14 (see Table 1). During this series, 2.5 mg/kg CPF or vehicle was administered once each weekday for 38 days. Grip strength was measured by using a Digital Grip strength meter (Columbus Instruments, Columbus, OH). Forelimb strength was measured by holding the rat by the nape of the neck and by the base of the tail. The forelimbs were placed on the tension bar, and the rat was pulled back gently until it released the bar. For measuring hindlimb grip strength, the hindlimbs were placed on the tension bar, and the rat was pulled toward the meter until it released.

**Ex Vivo and in Vitro Studies**

**Axonal Transport Studies.** The effects of repeated doses of CPF on fast anterograde and retrograde axonal transport were evaluated in single axons of sciatic nerves removed from animals previously exposed to CPF (or vehicle) by direct visualization of vesicle movement using video-enhanced differential interference contrast microscopy (AVEC-DIC). This procedure has been described in detail previously (Stone et al., 1999). Briefly, rats were anesthetized with 4% chloral hydrate (10 ml/kg), the mid-thigh sciatic nerve was exposed, and 6-0 silk ligatures were tied at the proximal and distal ends. Exceptional care was taken to prevent stretching and trauma to the nerve during excision. The proximal-to-distal orientation of the nerve was maintained throughout the experiment. The sample was placed in a custom-designed aluminum chamber between two coverslips, which were sealed in place with 1:1:1 Vaseline petroleum jelly/lanolin/paraffin. Before sealing the chamber, the nerve was extended to its original length, and the ligatures were attached to the bottom of the chamber using 1:1:1 Vaseline petroleum jelly/lanolin/paraffin. All procedures were accomplished with the nerve continuously submerged in oxygenated physiologic buffer (94 mM NaCl, 5 mM KCl, 1.5 mM CaCl₂, 1.0 mM MgSO₄, 2.0 mM Na₂HPO₄, 2.4 mM NaHCO₃, and 11 mM glucose, pH 7.4). Axons were viewed through a DIC microscope [Zeiss Axiocvert 10 microscope with DIC optics (Lehman Scientific, Red Lion, PA); Hamamatsu C2400-07 camera (Hamamatsu Corp., Bridgewater, NJ); Argus-20 image processor (Spectra Services, Inc., Webster, NY); and Hamamatsu high-resolution monitor], with the observation chamber on a 37°C heated stage (Zeiss TRZ model 3700). Video enhancement of the axons was achieved with analog contrast enhancement (camera controller) and digital contrast enhancement (video computer) with background subtraction. The number of vesicles moving in the anterograde and retrograde directions, which completely traversed a 2-cm square window (drawn directly on the screen of the video monitor), was counted for a 10-min interval.

**Preparation of Hippocampal Cultures.** Organotypic hippocampal cultures were prepared according to methods described previously (Prendergast et al., 2001). Briefly, whole brains from 8-day-old rat pups were aseptically removed and placed in dissection medium (4°C) made of minimum essential medium plus glutamine, 25 mM Hanks’ balanced salt solution, and 25 mM HEPES, 200 mM glutamine, and 50 μM penicillin/streptomycin solution. Bilateral hippocampi were dissected out and placed into culture medium at room temperature. Culture medium was made of dissection medium with the addition of 36 mM glucose, 25% (v/v) Hanks’ balanced salt solution, and 25% heat-inactivated horse serum. Each hippocampus was sectioned coronally at 400 μm using a McIlwain tissue chopper and placed into fresh culture medium. Each unilateral hippocampus yielded approximately 12 slices (24 per animal). Three slices were then transferred onto each Millicell-CM 0.4 μM biopore membrane insert (Millipore Corp., Bedford, MA) in preincubated culture medium. Inserts were then placed in 35-mm six-well culture plates, and excess medium on top of the slices was aspirated so that explants remained exposed to the atmosphere of 5% CO₂/95% air. Cultures were kept constantly at 37°C, and the medium was changed every 5 days. All culture medium solutions were supplied by Invitrogen (Carlsbad, CA) with the exception of heat-inactivated horse serum (Sigma-Aldrich, St. Louis, MO).
Assessment of Cytotoxicity. Hippocampal sections were allowed to acclimate to ex vivo conditions for 5 days then transferred to wells containing culture medium and the nonvital stain propidium iodide (PI; 2.5 mg/ml) or medium containing PI and one of three concentrations of CPF (10, 100, or 500 μM). Slices were exposed to their respective treatments for 8 continuous days. Uptake of propidium iodide was visualized using a 4× objective on a Nikon TE2000 microscope (Nikon, Melville, NY) fitted for fluorescence detection (mercury-arc lamp) connected to a personal computer via a charge-coupled device camera. Propidium iodide has a peak excitation wavelength of 536 nM and was excited using a band-pass filter exciting the wavelengths between 510 and 560 nM. The emission wavelength of propidium iodide is 620 nM in the visual range. Intensity of propidium iodide fluorescence was analyzed by densitometry using the image analysis program NIH Image (National Institutes of Health, Bethesda, MD). Optical intensity (in arbitrary optical units) was determined in the CA1 region of each individual slice culture. Comparisons were made between relative intensity of fluorescence in control slices and those exposed to CPF.

Statistical Analyses. Comparisons between treatment groups were made using analysis of variance (with repeated measures when necessary) followed by the Student-Newman-Keuls method for post hoc analysis. Statistical significance was assessed at an alpha level of 0.05. In all studies, the investigator performing experiments was blind to the treatment group.

Results

In Vivo Studies

Plasma Cholinesterase Activity. The dose-related effects of CPF on plasma cholinesterase activity assayed 24 h after single injections are illustrated in Fig. 1. As indicated, there were dose-related decreases (i.e., dose-effect, p < 0.001) in cholinesterase activity, ranging from approximately 30% inhibition with the 2.5 mg/kg dose to approximately 80% inhibition at the 100.0 mg/kg dose.

Body Weight, Rearing, and Sniffing Activity. The effects of repeated exposures (i.e., 14 days, one injection per day) to several doses of CPF or vehicle (see Table 1) on body weight and rearing and sniffing activity were assessed during six individual observation sessions (i.e., every 1–2 days) during dosing (see Fig. 2). Rats exposed to the 50 or 100 mg/kg daily dose of CPF developed significant tremors and other signs of OP toxicity (salivation and diarrhea) by the third to fourth observation session and were thus removed from the study and not evaluated further. These doses had initially been included for the higher end of the dose-effect range based on levels of plasma cholinesterase inhibition of roughly 60 and 80%, respectively, observed 24 h after injection (Fig. 1). The effects of these doses on body weight and rearing and sniffing activity prior to the appearance of overt signs of OP toxicity are presented in Figs. 2 and 3 but were not included in the statistical analysis. As indicated in Fig. 2, all animals exposed to CPF or vehicle (excluding the 50 and 100 mg doses) gained significant weight over the course of the 14 days of injections [i.e., observation-day effect, F(5,20) = 277.5, p < 0.001]. There was a highly significant dose-related effect of CPF on body weight over the course of the injections, however [i.e., all doses except 2.5 mg/kg decreased the overall magnitude of weight gain when compared with vehicle; dose effect F(4,57) = 3.9, p < 0.01, and dose by observation day interaction, F(20,283) = 3.0, p < 0.001]. All doses, including the 2.5 mg/kg dose of CPF, resulted in significant decreases in rearing and sniffing activity across the 14 days of injections (Fig. 3) [dose effect, F(4,57) = 26.7, p < 0.001; observa-

![Fig. 1. Dose-related inhibition of plasma cholinesterase activity by CPF assayed 24 h after a single subcutaneous injection. Each bar represents the mean (expressed as percent of vehicle control) ± S.E.M. n = 3 to 12 rats per group. * significantly different (p < 0.05; one-way ANOVA, Student-Newman-Keuls post hoc analysis) from vehicle control; #, significantly different from the 2.5 mg/kg CPF dose; +, significantly different from the 10.0 mg/kg CPF dose; and δ, significantly different from the 50.0 mg/kg CPF dose.](image1)

![Fig. 2. Effects of repeated exposures to CPF on body weight in male Wistar rats (n = 10–12). Body weight measurements were made during six observation sessions conducted throughout a series of daily subcutaneous injections of CPF (at the indicated doses) or vehicle for 14 days. Each point represents the mean ± S.E.M. * significantly (p < 0.05) different from vehicle control (two-way repeated-measures analysis of variance, Student-Newman-Keuls post hoc analysis), ** indicates that the 10.0, 18.0, and 25.0 mg/kg doses, respectively, were significantly different from vehicle controls during the observation sessions indicated. The 50.0 and 100.0 mg/kg doses were not included in the statistical analysis.](image2)
Observation Session

Fig. 3. Effects of repeated exposures to CPF on rearing and sniffing behavior in male Wistar rats (n = 10–12). Rearing and sniffing movements (i.e., total movements per animal per min) were recorded over a 20-min period during six observation sessions conducted throughout a series of daily subcutaneous injections of CPF (at the indicated doses) or vehicle for 14 days. Each point represents the mean ± S.E.M. *, significantly (p < 0.05) different from vehicle control (two-way repeated measures ANOVA, Student-Newman-Keuls post hoc analysis). ***, indicates that the 10.0, 18.0, and 25.0 mg/kg doses, respectively, were significantly different from vehicle controls during the observation session indicated. ****, indicates that the 2.5, 10.0, 18.0, and 25.0 mg/kg doses, respectively, were significantly different from vehicle controls during the observation sessions indicated. The 50.0 and 100.0 mg/kg doses were not included in the statistical analysis.

Water Maze Testing: 24-h Washout. Hidden Platform Test. The latencies and swim distances required to locate a hidden platform in the water maze beginning 24 h after a 14-day regimen of CPF exposure are illustrated in Fig. 4. Statistical comparisons of latencies across the five groups revealed the following results: dose effect, F(4,48) = 21.7, p < 0.001; day effect, F(3,12) = 43.2, p < 0.001; and dose × day interaction, F(12,144) = 3.1, p < 0.001. Similar results were evident when swim distances were analyzed. Thus, after exposure to vehicle or doses of 2.5 or 10 mg/kg CPF for 14 days, the rats learned to locate the hidden platform with progressively shorter latencies (and swim distances) across the 4 days of training. However, both the 18.0 and 25.0 mg/kg doses were associated with significant (p < 0.05) impairments in performance of the task (i.e., indicated by higher mean latencies and distances swam to locate the hidden platform).

Transfer Test (Probe Trials). The effects of CPF on spatial bias are presented in Fig. 5 as the percentage of time spent and distance swam in the quadrant where the platform had been located during the first 4 days of testing and the number of crossings over the previous platform location (i.e., the 10-cm square area). All treatment groups preferred the previous target quadrant (as opposed to the other three quadrants), as indicated by a greater-than-chance (i.e., 25%) percentage of time spent and distance swam in this region of the pool (p < 0.05, one-tailed t tests). The higher doses of CPF (18.0 and 25.0 mg/kg) were associated with inferior performance of probe trials, however, as indicated by the reduced number of platform area crossings compared with vehicle controls, F(4,49) = 22.1, p < 0.02 (Fig. 5C). For the percentage time and distance measurements, the 18.0 mg/kg dose was associated with impaired performance, whereas impairment associated with the 25.0 mg/kg dose did not reach statistical significance (i.e., p > 0.05), possibly due to the level of variance.

Swim Speeds. Swim speeds (i.e., distance swam in centimeters per latency to find the platform in seconds = cm/s) were compared daily across the treatment groups for all 5 days of water maze testing and appear in Fig. 6. Statistical comparisons revealed significant dose-related differences in swim speeds among the treatment groups after 14 days of exposure, dose effect, F(4,48) = 4.8, p < 0.01; day effect, F(4,16) = 18.5, p < 0.001; and without a significant dose × day interaction, F(16,192) = 1.5, p < 0.1. Post hoc analyses indicated that the animals previously exposed to CPF at 18.0 or 25.0 mg/kg swam significantly (p < 0.05) slower than did controls.

Visible Platform Studies. The average times required to reach a highly visible (reflective) platform ranged between 12 and 30 s across all groups in the study and were not significantly different (i.e., all p values were >0.05), indicating that differences in performance of the previous hidden platform tests or probe trials were unlikely to be a result of impaired visual acuity associated with CPF.

Water Maze Testing: 2-Week Washout. Following water maze studies conducted after a 1-day (24 h) washout from the various treatment groups were completed, we were interested to learn whether residual effects associated with the higher dose of CPF persisted after a longer washout interval. Additional rats (see Table 1) were administered either vehicle or CPF, 25.0 mg/kg daily for 14 days, then given a 2-week washout and tested in the various water maze procedures. The results of these tests are presented in a composite figure (Fig. 7). There were no statistically significant differences (i.e., all p values were >0.05) in the hidden platform test, in probe trials, or on swim speeds, indicating that the animals...
previously treated with 25.0 mg/kg CPF for 14 days had fully recovered (i.e., memory-related performance) after a 2-week washout.

**Ex Vivo and in Vitro Studies**

**Axonal Transport Studies.** 24-h Washout. The effects of repeated exposures to several doses of CPF on bidirectional, fast axonal transport (ex vivo) in peripheral (sciatic) nerve axons after the 1-day washout and water maze testing (i.e., axons evaluated 6 days after the last CPF injection) are illustrated in Fig. 8. Deficits in both anterograde and retrograde transport were observed in the animals given the 10.0, 18.0, and 25.0 mg/kg doses compared with controls [anterograde transport-dose effect, $F(4,12) = 18.8, p < 0.001$; and retrograde transport-dose effect, $F(4,12) = 14.4, p < 0.001$].

14-Day Washout. The effects of CPF 25.0 mg/kg (14-day chronic regimen), after water maze testing and an additional 14-day washout (i.e., 20 days after the last CPF injection), are illustrated in Fig. 9. As illustrated, subtle but significant deficits in bidirectional axonal transport were still observed for up to 20 days after the last CPF injection [anterograde transport-treatment effect, $p = 0.05$; and retrograde transport-treatment effect, $p = 0.03$ (t tests)].

**Organotypic Hippocampal Culture Experiments.** The cytotoxic effects of CPF on organotypic hippocampal slices are illustrated in Fig. 10. At 1 day and 8 days after the initiation of CPF exposure, relative uptake of PI was quantified via fluorescent microscopy, as described under Materials and Methods. Figure 10A provides representative examples of slices (and the level of propidium iodide uptake) under control conditions (media only) compared with slices that had been exposed to 500 $\mu$M CPF (parent compound) for 24 h or 8 days. Figure 10B illustrates the concentration-related effects of CPF exposure after 1 and 8 days of exposure. CPF did not markedly alter neuronal viability in slices when examined 24 h after the beginning of exposure, indicating the absence of acute toxicity. However, 8 days of continuous exposure to CPF (at 100 and 500 $\mu$M) produced significant cell death in the CA1 region of the hippocampus ($p < 0.05$ versus control), as indicated by enhanced uptake of propidium iodide.

**Grip Strength.** The effects of repeated administration of a subthreshold dose (2.5 mg/kg) of CPF administered 5 days/week over 38 days on grip strength appear in Fig. 11. The purpose of this experiment was to determine whether such an extended regimen could lead to impairment of motor function in the absence of other overt symptoms of toxicity. After...
4 weeks of treatment, hindlimb grip strength declined [treatment by day interaction, $F(140,175) = 2.8$, $p < 0.01$; significant on experimental day 39, post hoc analysis, $p < 0.05$], even though weight gain was not different from controls. A similar trend was observed for the forelimb measurements, although the treatment by day interaction did not reach statistical significance (i.e., $p > 0.05$). The reductions in grip strength appeared to be reversible after discontinuation (Fig. 11, arrow) of the CPF regimen.

Discussion

The initial experiments outlined in this report indicated that all of the doses of CPF examined (even doses as low as 2.5 mg/kg, which had only mild effects on plasma cholinesterase and no effects on weight gain) significantly decreased typical exploratory behaviors in rats. These behaviors, namely rearing (i.e., vertical activation) and sniffing activity reflect responses to environmental novelty as well as the emotional state (e.g., stress level) in rodents (Gironi Carnevale et al., 1990; Sadile, 1996). Rearing responses observed upon repeated exposures to the same environment are strongly influenced by interindividual differences in habituation learning, a variety of pharmacologic and toxicologic agents, and, interestingly, cholinergic activity in the forebrain and hippocampus (Thiel et al., 1998).

Daily doses of 2.5 to 25.0 mg/kg CPF for 14 days did not elicit any other overt signs of OP toxicity; however, the two higher doses (18.0 and 25.0 mg/kg) impaired water maze performance and swim speeds for up to 5 days after discontinuation of dosing. The dose-effect relationship for CPF in altering maze performance was very steep, with less than 1 log unit of dosing separating an absence of effect from a near maximal effect. Although swim speeds were reduced at the higher doses of CPF, differences in task performance could not be entirely attributed to motor deficits, as indicated by the facts that all groups clearly preferred the target quadrant.
over the other three quadrants) in probe trials on day 5 and
that all groups were able to perform the visible platform task
equally well. At 2 weeks after discontinuation of CPF 25.0
mg/kg (in a separate group of animals), all aspects of water
maze performance (i.e., latencies to find the hidden platform,
swim speeds, and performance of probe trials) were indistin-
guishable from vehicle controls, indicating a full recovery of
memory-related behavioral function.

The next series of experiments were performed to assess
the effects of CPF on axonal transport. The impetus for these
experiments came from the results of previous studies in
which repeated subthreshold exposures to the OP acetylcho-
linesterase inhibitor, diisopropyl fluorophosphate (DFP) im-
paired working memory in nonhuman primates as well as
spatial learning in rats (Prendergast et al., 1997, 1998) that
persisted for up to 21 days after drug discontinuation. The
DFP regimen also resulted in a protracted decrease in the
expression of central nicotinic and muscarinic acetylcholine
receptors (Stone et al., 2000). The reason for this delayed
recovery of cholinergic receptors was unclear but was hypoth-
esized to result from direct or indirect interactions of the OP
with microtubular transport proteins. We formulated this
hypothesis based on previous reports of accumulations of
tubulovesicular profiles within axons exposed to neurotoxic
doses of OPs (Abou-Donia and Lapadula, 1990). We predicted
that similar processes might occur with repeated exposures
to lower OP doses or agents considered non-neuropathic,
such as CPF.

In the present study, both anterograde and retrograde
axonal transport (measured in sciatic nerves derived from
study animals) were impaired at 6 days after discontinuation
of the 14-day, 10.0, 18.0, and 25.0 mg/kg CPF regimen, thus
supporting the water maze deficits in the first series of ex-
periments. Surprisingly, measurable deficits in axonal trans-
port persisted for up to 20 days after discontinuation of the 14
day, 25.0 mg/kg regimen, even though water maze task per-
formance appeared normal. These findings suggest that
there is a threshold level of axonal transport impairment
before water maze deficits are detectable and that longer

Fig. 9. Residual effects of CPF 25.0 mg/kg (14-day repeated-dose regi-
men; n = 10) or vehicle on fast bidirectional axonal transport ex vivo after
water maze testing and an additional 14-day washout. Axonal transport
was thus measured in peripheral nerve axons 20 days after the last CPF
injection by video-enhanced differential interference contrast microscopy.
A, anterograde axonal transport; B, retrograde axonal transport. *, signifi-
ificantly (p ≤ 0.05) different from vehicle control (one-way ANOVA,
Student-Newman-Keuls post hoc analysis).

Fig. 10. Hippocampal cytotoxicity produced by prolonged exposure to
CPF at the indicated concentrations. Organotypic hippocampal cultures
from 8-day-old rat pups were exposed to control (medium) or CPF (dis-
solved in medium) for either 24 h or 8 days. A, representative hippocam-
pal slices exposed to control conditions or CPF 500 μM for the time
periods indicated. B, concentration-dependent effects of CPF for the time
periods indicated. Relative uptake of propidium iodide was quantified via
fluorescent microscopy. *, significantly (p < 0.05) different from vehicle
control (one-way ANOVA, Student-Newman-Keuls post hoc analysis).
times of exposure to CPF (i.e., greater than 14 days) could, in fact, result in more prolonged (and adverse) cellular and, perhaps, behavioral effects.

As indicated above, the residual effect (through 5 days after CPF discontinuation) of CPF was associated with substantial impairments of the water maze task, a learning paradigm dependent upon intact hippocampal function (Morris et al., 1982). This finding and similar findings after DFP administration led to the next experimental series to determine whether CPF could induce cytotoxic effects directly on hippocampal cells (see below). Although the oxon metabolite of CPF is considered the active moiety in vivo due to its inhibitory effects on acetylcholinesterase activity, we were interested to determine whether the parent compound itself might also be cytotoxic. Few studies have been designed to study the direct neurotoxic properties of CPF, even though there are a number of published reports that would support such experiments. For example, although both the CPF parent compound and its principal metabolites are eliminated relatively rapidly in humans (i.e., metabolized and then eliminated primarily through the kidneys; U.S. National Library of Medicine, 1995), studies in rats (National Academy of Sciences, 1982) and other mammalian species (Gallo and Lawryk, 1991) indicate that CPF is redistributed to adipose tissue, forming a depot for slow release. Thus, the OP may be retained for longer periods than is evident using plasma measurements. Furthermore, when CPF was fed to cows, unchanged pesticide was found in the feces but not in the urine or milk (U.S. Environmental Protection Agency, 1984). However, it was detected in the milk of cows for 4 days following spray dipping (Gallo and Lawryk, 1991).

Organotypic hippocampal cultures were selected for experiments designed to investigate the direct effects of CPF on the hippocampus, for several reasons. The preparations retain the connective neuronal organization found in situ but yet are readily accessible to experimental manipulation and are quite sensitive to pathological insults (Bahr, 1995). Cellular damage/death in hippocampal slices can be assessed by incubation of slices with the nucleic acid stain PI, since uptake by hippocampal cells of PI is observed only after lysis of cells. The use of this method for detecting cytotoxicity has wide acceptance, and the intensity of fluorescence has been shown to correlate very well with other measures of cell death, such as release of lactate dehydrogenase (Abdel-Hamid and Tymianski, 1997). As indicated under Results, 8 days of continuous exposure to CPF (100 or 500 μM) produced significant cell death in the CA1 region of the hippocampus. These data are physiologically significant, since they provide direct evidence that CPF may be neurotoxic (especially with extended exposure) irrespective of its indirect effects on acetylcholinesterase. Whole-body molar concentrations associated with the doses of CPF (i.e., 2.5–25.0 mg/kg) used in behavioral experiments were calculated as ranging between approximately 7.0 and 8.0 to 70.0 and 80.0 μM. Since these doses were administered for 14 consecutive days, these concentrations certainly appear relevant to the lower in vitro concentration (100 μM) that was associated with significant hippocampal cytotoxicity.

The final experiments performed in this study were designed to determine whether a low dose of CPF might have measurable effects on motor strength if administered for longer time periods. Low-level (2.5 mg/kg), intermittent (5 days/week) administration of CPF for 38 days impaired grip strength in rats without causing any other discernible side effects. Although the effect partially abated toward control values within 6 days of the exposure regimen, the data show that the toxicant does have the potential to produce neuropathic changes with long-term exposure. These data are consistent with our findings of prolonged decreases in axonal transport after repeated CPF exposure.

The observations described in this report are, therefore, important, because they begin to address the cellular and behavioral consequences of repeated exposures to doses of OPs that produce no overt signs of acute toxicity. Previously, the interactions of OPs with the enzymes acetylcholinesterase and neurotoxic esterase have been the major focus of most mechanistic studies used to explain both acute and long-term effects of overtly toxic doses of a variety of OPs. The issue of repeated, subthreshold exposures to OPs is very important, since detectable levels of OPs (including CPF) can remain in the environment (particularly indoor environments) for extended periods after application (Krieger et al.,
thereby posing an ongoing risk for low-level exposure. Furthermore, a variety of nonspecific symptoms of OP exposure have been suspected (but difficult to attribute directly to OPs) or have been unrecognized as symptoms of OP toxicity for many years. These symptoms include fatigue, anorexia, headache, chest tightness, dizziness, and sweating (Abou-Donia and Lapadula, 1990), as well as psychiatric sequelae, including anxiety, depression, apathy, irritability, and even schizophriform manifestations (Metcalf and Holmes, 1969; Karczmar, 1984). Information such as that described in this report may lead to a better understanding of the mechanisms that underlie such symptoms.

In conclusion, the results of this study indicate that the threshold for neurotoxic consequences (usually associated with higher doses of OPs) may be exceeded during repeated exposure to subthreshold doses of OPs, even for agents like CPF that have been considered moderately toxic or non-neuropathic. One potential mechanism for these observations is the prolonged inhibition of fast axonal transport. Finally, it is also important to note that CPF itself may have neurotoxic properties in the absence of conversion to its oxon or other metabolites. Although many of the toxic consequences of low-dose CPF administration were shown to be reversible after discontinuation, the cytotoxic action observed ex vivo suggests that under certain conditions of exposure, some actions may prove to be longer lasting.

References
Address correspondence to: Dr. Alvin V. Terry, Jr., University of Georgia College of Pharmacy and Alzheimer’s Research Center, CJ-1020, The Medical College of Georgia, Augusta, GA 30912. E-mail: aterry@mail.mcg.edu